A detailed history of Smith Shellnut Wilson LLC transactions in Amgen Inc stock. As of the latest transaction made, Smith Shellnut Wilson LLC holds 1,144 shares of AMGN stock, worth $363,197. This represents 0.18% of its overall portfolio holdings.

Number of Shares
1,144
Previous 1,144 -0.0%
Holding current value
$363,197
Previous $325,000 9.85%
% of portfolio
0.18%
Previous 0.17%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 04, 2023

SELL
$214.27 - $253.37 $4,285 - $5,067
-20 Reduced 1.72%
1,144 $253,000
Q2 2022

Aug 02, 2022

SELL
$230.71 - $256.74 $9,228 - $10,269
-40 Reduced 3.32%
1,164 $283,000
Q1 2022

May 02, 2022

SELL
$219.27 - $242.57 $4,823 - $5,336
-22 Reduced 1.79%
1,204 $291,000
Q4 2021

Feb 03, 2022

BUY
$198.88 - $227.6 $4,972 - $5,690
25 Added 2.08%
1,226 $276,000
Q3 2021

Nov 12, 2021

SELL
$212.27 - $248.7 $8,915 - $10,445
-42 Reduced 3.38%
1,201 $255,000
Q2 2021

Aug 12, 2021

BUY
$233.58 - $259.14 $30,598 - $33,947
131 Added 11.78%
1,243 $303,000
Q1 2021

Apr 06, 2021

SELL
$221.91 - $258.6 $22,412 - $26,118
-101 Reduced 8.33%
1,112 $277,000
Q3 2020

Nov 12, 2020

SELL
$234.65 - $260.95 $30,739 - $34,184
-131 Reduced 9.75%
1,213 $308,000
Q1 2020

Apr 20, 2020

SELL
$182.24 - $241.7 $26,242 - $34,804
-144 Reduced 9.68%
1,344 $272,000
Q3 2019

Nov 06, 2019

SELL
$174.11 - $208.62 $16,192 - $19,401
-93 Reduced 5.88%
1,488 $288,000
Q1 2019

May 14, 2019

BUY
$180.87 - $203.88 $29,481 - $33,232
163 Added 11.5%
1,581 $300,000
Q1 2018

Apr 24, 2018

SELL
$169.43 - $198.0 $179,087 - $209,286
-1,057 Reduced 42.71%
1,418 $242,000
Q3 2017

Nov 17, 2017

BUY
$167.29 - $191.0 $414,042 - $472,725
2,475
2,475 $461,000

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $170B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Smith Shellnut Wilson LLC Portfolio

Follow Smith Shellnut Wilson LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Smith Shellnut Wilson LLC , based on Form 13F filings with the SEC.

News

Stay updated on Smith Shellnut Wilson LLC with notifications on news.